Global Osteoporosis Drugs Market; Drivers and Restraints in the Healthcare Insustry, MRFR Unleashes the Forecast by 2022

Market Research Future adds the “Global Osteoporosis Drugs Market Research Report - Forecast to 2022” report to their unique and vast collection.

Pune, India - June 12, 2019 /MarketersMedia/ —

Osteoporosis is a disorder that causes a lower bone mass that results in weakening and micro-architectural deterioration of bone tissues.  Osteoporosis makes bones so brittle that a minor injury or even mild stresses like bending over or coughing can cause a fracture. Osteoporosis drugs are useful in the treatment of low bone density, slowing down bone resorption. These medications reduce the likelihood of having fragility fractures.

The global osteoporosis drugs market is well-established, and there are various effective medicines available to treat the disorder which is invariably driving the growth of the market. Moreover, a growing number of drug manufacturers are escalating the market on the global platform, bringing novel medications in the market.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2479

Recognizing the colossal traction and gauging the potential of the market to grow in forthcoming years; Market Research Future (MRFR), in its newly published study analysis asserts that the global osteoporosis drugs market will reach a valuation of USD 14,300 MN by 2022, growing at7.2% CAGR over the review period (2017 – 2022).

Additional factors helping the market to grow further include the rise in the geriatric population, gene mutations, changing lifestyle, and addictions such as alcoholism and smoking. Also, drug-induced osteoporosis and rising prevalence of diseases and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, and hormonal disorders, are some of the key factors propelling the growth of the market.

Conversely, factors such as the patent expiries of blockbuster medicines, side effects of these drugs, and the availability of generics are impeding the growth of the market. Also, in some cases, osteoporosis shows very low or poor symptoms which obstructs the market growth.

Nevertheless, factors such as substantial technological strides that have made the osteoporosis drugs more effective, increasing the demand for the treatment measures for osteoporosis are expected to fuel the growth of the market. 

Besides, substantial investments transpired into R&D activities, and improving economic conditions would provide impetus to the growth of the market, increasing the healthcare expenditures and access to excellent health care.

Global Osteoporosis Drugs Market – Segments

For ease of understanding, the analysis has been segmented into four key dynamics: -

By Drug Class                                  : Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), and Parathyroid Hormone (PTH) among others.

By Route Of Administration     : Oral and Injectable among others.

By Gender                                       : Male and Female

By Regions                                      : North America, Asia Pacific, Europe, and the Rest-of-the-World.

Global Osteoporosis Drugs Market – Regional Analysis

The North American region, heading with the increasing prevalence of osteoporosis is estimated to retain its dominance over the global osteoporosis drugs market. Additional factors such as the presence of a well-developed healthcare sector, high per capita healthcare expenditures, and well-spread awareness drives the regional market.

Furthermore, growing markets in the U.S. and Canada backed by the presence of prominent market players impacts the growth of the regional market, positively.  The region is expected to create a significant revenue pocket registering a robust CAGR throughout the forecast period (2017-2022).

The osteoporosis market in the European region accounts for the second-largest market, globally. Factors such as favorable government support and initiatives and the proliferating healthcare sector backed by the resurging economy are radiantly fostering the growth of the market in the region.

The U.K., backed by its sizeable osteoporosis drugs market and Germany with its vast medical technology and pharmaceutical industry, significantly contributes to the growth of the regional market, is expected to drive the market growth in the region. 

The Asia Pacific osteoporosis drugs market is rapidly emerging as a promising market, globally. Factors such as the spreading awareness towards the disorder and women healthcare alongside the availability of many novel drugs influence the growth of the market, positively.

Moreover, the rising prevalence of osteoporosis in women after menopause, gene mutations, changing lifestyle, and the burgeoning pharmaceutical industry support the growth of the regional market. Furthermore, continually rising healthcare expenditures and favorable government policies, especially in the developing countries like China and India substantiate the market growth in the APAC region.

Browse Complete 84 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479

Global Osteoporosis Drugs Market – Competitive Analysis

Fiercely competitive, the osteoporosis drugs market appears fragmented with many large and small players churning the competition. Through the strategic initiatives such as partnership, expansion, acquisition, collaboration, and product & technology launch these players try to gain an edge over their competitors.

Major Players:

Key players leading the global osteoporosis drugs market include Merck & Co., Eli Lilly and Company, Novartis International AG, F. Hoffmann La Roche Ltd., Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Novo Nordisk among others.

Industry, Innovation & Related News

April 16, 2019 –--- Two leading global biopharmaceutical companies UCB (Belgium) and Amgen Inc. (the US) announced the receiving of the US FDA approval for the osteoporosis drug – Evenity that they have developed, collaboratively. This drug is approved to treat osteoporosis in postmenopausal women at high risk of bone fracture. Evenity represents the first new treatment approach after nearly two decades, restoring bone without breaking it down. Based on a rare gene mutation in people with bones so dense that they never break, Evenity, can increase bone formation and decrease bone loss.

Send an Enquiry @ https://www.marketresearchfuture.com/enquiry/2479

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Market Research Future
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India
Phone: +1 646 845 9312
Website: https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479

Source URL: https://marketersmedia.com/global-osteoporosis-drugs-market-drivers-and-restraints-in-the-healthcare-insustry-mrfr-unleashes-the-forecast-by-2022/523312

Source: MarketersMedia

Release ID: 523312

Latest News

APNewsBreak: US government unveils final Utah monument plan

Aug 26, 2019

SALT LAKE CITY — The U.S. government's final management plan for land in and around a Utah national monument that President Donald Trump downsized doesn't include many new protections for the cliffs, canyons, waterfalls and arches found there, but it does include a few more safeguards than were in a proposal issued last year. The Bureau of Land Management's plan for the Grand Staircase-Escalante National Monument in southwestern Utah codifies that the lands cut out of the monument will be open to mineral extraction such as oil, gas and coal as expected, according to a plan the agency provided to...

Shard reveals how Cyprus' ancient kingdoms managed economy

Aug 26, 2019

NICOSIA, Cyprus — The discovery of a small clay shard inscribed with a partial inventory of goods at a 2,500-year-old citadel suggests that Cyprus' ancient city states "more than likely" managed their economies using a homegrown system, not an imported one, an archaeologist said Wednesday. University of Cyprus Professor Maria Iacovou told The Associated that the recent discovery at the ancient kingdom of Paphos on Cyprus' southwestern coast refutes the notion that Cypriot city states managed their economies based on systems brought over from foreign kingdoms, like those of neighboring Phoenician city states. The inscription on the shard was in...

Scientists say monster penguin once swam New Zealand oceans

Aug 26, 2019

WELLINGTON, New Zealand — Scientists in New Zealand said Wednesday they've found fossilized bones from an extinct monster penguin that was about the size of an adult human and swam the oceans some 60 million years ago. They said the previously undiscovered species is believed to have stood about 1.6 meters (5 feet 2 inches) tall and weighed up to 80 kilograms (176 pounds). It's believed to have been one of several species of giant penguins that thrived soon after dinosaurs died out. The findings were published this week in "Alcheringa: An Australasian Journal of Palaeontology." Paul Scofield, a co-author...

Gazans struggle to protect antiquities from neglect, looting

Aug 26, 2019

KHAN YOUNIS, Gaza Strip — Walid al-Aqqad's Gaza home would be the envy of many an antiquities collector. Pieces of Corinthian columns greet visitors in the backyard. Inside, hundreds of ancient pots and other artifacts hang on the walls or are arranged helter-skelter on shelves. They are remnants of five millennia of Gaza's history, from the Bronze Age to the Islamic caliphates and on down to the years of Ottoman and British rule in the 20th century. A sliver of land on the Mediterranean, Gaza was a major trade route between Egypt and the Levant going back to ancient times....

T-Mobile's $26.5B Sprint deal OKed despite competition fears

Aug 26, 2019

WASHINGTON — U.S. regulators have approved T-Mobile's $26.5 billion takeover of rival Sprint, despite fears of higher prices and job cuts, in a deal that would leave just three major cellphone companies in the country. Friday's approval from the Justice Department and five state attorneys general comes after Sprint and T-Mobile agreed to conditions that would set up satellite-TV provider Dish as a smaller rival to Verizon, AT&T and the combined T-Mobile-Sprint company. The Justice Department's antitrust chief, Makan Delrahim, said the conditions set up Dish "as a disruptive force in wireless." But attorneys general from other states and public-interest...

About Us

Science Thread delivers quality and fascinating science and technology content that matters on a daily basis and makes it go viral.

Contact us: sales@sciencethread.com